Richard J. Mark
Richard J. Mark's purchase track record
How the stock did after each of Richard J. Mark's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/11/2026 | SRE | $251K | -1.2% | -7.1% | +12.7% |
| 3/6/2025 | SRE | $500K | +10.1% | +20.1% | +13.3% |
| 5/17/2024 | SRE | $150K | +3.2% | +19.8% | +10.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Sempra Analysts Maintain Ratings, Lower Targets. Multiple analysts have maintained their positive ratings on Sempra while lowering their price targets, suggesting adjusted but favorable outlooks. A news article comparing Edison International and Eversource provides context on competitive advantages in the utility sector, which may be relevant for Sempra.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Ameren Highlights AI Data Center Power Demand and Upcoming Earnings. Ameren is in the news for its role in the growing AI data center power demand, a trend that has lifted several utility stocks. Analysts have adjusted their price targets, with Truist lowering its target to $116 and Keybanc raising it to $122, reflecting differing views on the company's outlook. The company will host a third‑quarter 2026 earnings webcast on Nov. 6, 2026, and a SeekingAlpha piece highlights Ameren as a long‑term dividend growth play.
Transaction History
| THC | ▼ Sell | Open Market | 10,000 | $2.6M | 9/10/2026 | View on chart |
| THC | ▲ Buy | Option Exercise | 1,333 | — | 5/22/2026 | View on chart |
| THC | ▼ Sell | Other | 493 | $86K | 5/22/2026 | View on chart |
| SRE | ▲ Buy | Grant | 1,499 | $0 | 5/12/2026 | View on chart |
| SRE | ▲ Buy | Open Market | 2,692 | $251K | 3/11/2026 | View on chart |
| THC | ▲ Buy | Option Exercise | 1,551 | — | 5/23/2025 | View on chart |
| THC | ▼ Sell | Other | 573 | $92K | 5/23/2025 | View on chart |
| SRE | ▲ Buy | Grant | 1,864 | $0 | 5/13/2025 | View on chart |
| SRE | ▲ Buy | Grant | 1,864 | $0 | 5/13/2025 | View on chart |
| SRE | ▲ Buy | Open Market | 7,160 | $500K | 3/6/2025 | View on chart |
| SRE | ▲ Buy | Open Market | 1,925 | $150K | 5/17/2024 | View on chart |
| SRE | ▲ Buy | Grant | 1,642 | $0 | 5/9/2024 | View on chart |
| THC | ▼ Sell | Open Market | 14,000 | $1.4M | 3/12/2024 | View on chart |
| SRE | ▲ Buy | Grant | 1,807 | $0 | 9/5/2023 | View on chart |
| THC | ▲ Buy | Grant | 2,846 | $0 | 5/26/2023 | View on chart |
| THC | ▲ Buy | Grant | 3,836 | $0 | 5/9/2022 | View on chart |
| AEE | ▼ Sell | Open Market | 6,000 | $562K | 3/31/2022 | View on chart |
| AEE | ▼ Sell | Open Market | 3,500 | $306K | 3/10/2022 | View on chart |
| THC | ▼ Sell | Open Market | 6,000 | $543K | 3/9/2022 | View on chart |
| AEE | ▼ Sell | Tax Withholding | 7,205 | $619K | 2/28/2022 | View on chart |
| AEE | ▲ Buy | Grant | 3,405 | $0 | 2/10/2022 | View on chart |
| AEE | ▲ Buy | Grant | 14,500 | $0 | 2/10/2022 | View on chart |
| AEE | ▼ Sell | Open Market | 6,000 | $493K | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Tenet Healthcare Raises 2026 Outlook, Analysts Lift Targets
Tenet Healthcare recently raised its 2026 financial outlook, prompting analysts like Guggenheim to increase price targets to $307. This positive guidance has driven the stock higher, with the average analyst target now sitting at $285.32. While the company is trading near its 52-week high, questions remain about whether this recent strength is fully reflected in the current valuation.
Tenet Healthcare Raises 2026 Outlook, Analysts Lift Targets. Tenet Healthcare recently raised its 2026 financial outlook, prompting analysts like Guggenheim to increase price targets to $307. This positive guidance has driven the stock higher, with the average analyst target now sitting at $285.32. While the company is trading near its 52-week high, questions remain about whether this recent strength is fully reflected in the current valuation.